

## **Agreement with patientorganisation -**

### **1. Parties**

The undersigned

Incyte Bioscience AB

(hereinafter the "Company")

and

co-signatory

LYLE – Patientforeningen for Lymfekræft, Leukemi og MDS

(hereinafter the "Organisation")

(hereinafter referred to jointly as the "Parties")

have agreed to collaborate as follows.

### **2. Purpose of the Agreement**

Incyte Biosciences Nordic AB engages the PAG member to participate in a Nordic meeting in Stockholm, December 12.-13., 2018 with the purpose of knowledge and experience sharing with other Nordic patient advocacy groups and to discuss topics such as how blood cancer patients in the Nordics can get more personalized treatment and how monitoring and mutational testing can benefit the treatment process. Participants will furthermore learn more about monitoring, mutational testing and ELN guidelines in the Nordics.

### **3. Name of the collaborative project**

The name of the collaborative project shall be: **PAG Nordic Round Table Meeting**

### **4. Roles of the collaborating parties**

The company shall undertake during the term of the agreement to arrange and facilitate til Nordic meeting. Incyte will pay all expenses with the Nordic participants, including transport, meetings facilitation, hotel and food during the stay.

The Organisation undertakes during the term of this Agreement to plan and facilitate the meeting.

### **5. Timescale**

This agreement, the purpose and scope of which are described in Arts. 2 and 4 shall run from December 12th to December 13th at Grand Central by Scandic in Stockholm. The rights and obligations of the Parties under this Agreement shall run from signature date and unless otherwise expressly agreed, until the obligations of the Agreement shall have been fulfilled.

## **6. Financial commitment**

The Company's financial commitment under this Agreement shall be in the sum of DKK 75.000, exclusive of VAT, and shall be used for participants transport (Transport (taxi, train, flight tickets), meeting facilities, hotel and food.

## **7. Non-financial commitment**

The company's non-financial commitment shall be to plan and complete the Nordic PAG meeting.

## **8. Disclosure**

This Agreement shall be publicly disclosed on the Company's website [www.incyte.com](http://www.incyte.com) until November 2020

The company calls attention to the fact that the legislation obliges the patient associations to publish on their web site all financial benefits, including financial sponsorships (sum of money) and benefits-in-kind that the association has received from pharmaceutical companies cf. the Executive Order on Advertising, etc., of Medicinal Products. The publication shall be conducted in a way that the size of financial benefits of each individual company appears from the web site. The information shall be made available on the web site no later than a month after the patient association has received the financial benefits. The information shall be available on the web site for at least two years.

## **9. Use of the Organisation's logo**

The Organisation shall agree to the Company's use of the Organisation's logo or name, or that it in some other way makes use of collaboration with the Organisation, as follows: On material that concerns the Nordic PAG meeting.

## **10. Independence and conflict of interest**

The Parties declare in signing this Agreement that the Organisation shall be free to collaborate with several pharmaceutical companies and that the Company shall be free to collaborate with one or more organisations. The Parties further state that their relations shall not involve exclusive rights with respect to specific product or therapeutic areas.

The Company agrees in signing this Agreement not to impose conditions for the Organisation's professional or stakeholder-policy viewpoints.

The Company agrees in signing this Agreement that it has no executive duties in the Organisation that have any significance for the present Agreement.

## **11. Breach of Agreement**

If one of the Parties is in breach of its obligations under this Agreement, the other party may terminate the Agreement with immediate effect and the latter party shall be entitled to seek other legal redress in Danish law for breach of agreement, including a claim for compensation irrespective of whether the Agreement shall have been terminated.

## 12. Law

This Agreement shall be subject in every respect to Danish law.

## 13. Dispute resolution

If disputes cannot be resolved by mediation, they shall be brought before the Maritime and Commercial Court in Copenhagen.

## 14. Signatures

Copenhagen, Denmark

### **Incyte Biosciences AB**

Barnhusgatan 3, 4<sup>th</sup> floor  
111 23 Stockholm

Name: Dag Martin Fuhr Solvang

Title: \_\_\_\_\_

### **LyLe – Patientforeningen for Lymfekræft, Leukæmi og MDS**

Banetoften 26  
4700 Næstved

Name: Rita O. Christensen

President: 